Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial

Carmen J. Allegra, Greg Yothers, Michael J. O'Connell, Robert W. Beart, Timothy F. Wozniak, Henry Clement Pitot, Anthony F. Shields, Jerome C. Landry, David P. Ryan, Amit Arora, Lisa S. Evans, Nathan Bahary, Gamini Soori, Janice F. Eakle, John M. Robertson, Dennis F. Moore, Michael R. Mullane, Benjamin T. Marchello, Patrick J. Ward, Saima SharifMark S. Roh, Norman Wolmark

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

Background: National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for continuous infusion 5-FU in the curative setting of stage II/III rectal cancer during neoadjuvant radiation therapy and whether the addition of oxaliplatin could further enhance the activity of fluoropyrimidine-sensitized radiation. Methods: Patients with clinical stage II or III rectal cancer undergoing preoperative radiation were randomly assigned to one of four chemotherapy regimens in a 2x2 design: CVI 5-FU or oral capecitabine with or without oxaliplatin. The primary endpoint was local-regional tumor control. Time-to-event endpoint distributions were estimated using the Kaplan-Meier method. Hazard ratios were estimated from Cox proportional hazard models. All statistical tests were twosided. Results: Among 1608 randomized patients there were no statistically significant differences between regimens using 5-FU vs capecitabine in three-year local-regional tumor event rates (11.2% vs 11.8%), 5-year DFS (66.4% vs 67.7%), or 5-year OS (79.9% vs 80.8%); or for oxaliplatin vs no oxaliplatin for the three endpoints of local-regional events, DFS, and OS (11.2% vs 12.1%, 69.2% vs 64.2%, and 81.3% vs 79.0%). The addition of oxaliplatin was associated with statistically significantly more overall and grade 3-4 diarrhea (P < .0001). Three-year rates of local-regional recurrence among patients who underwent R0 resection ranged from 3.1 to 5.1% depending on the study arm.

Original languageEnglish (US)
Article numberdjv248
JournalJournal of the National Cancer Institute
Volume107
Issue number11
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Allegra, C. J., Yothers, G., O'Connell, M. J., Beart, R. W., Wozniak, T. F., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., Arora, A., Evans, L. S., Bahary, N., Soori, G., Eakle, J. F., Robertson, J. M., Moore, D. F., Mullane, M. R., Marchello, B. T., Ward, P. J., ... Wolmark, N. (2015). Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial. Journal of the National Cancer Institute, 107(11), [djv248]. https://doi.org/10.1093/jnci/djv248